Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Journey Medical (DERM) EBIT Margin: 2020-2025

Historic EBIT Margin for Journey Medical (DERM) over the last 5 years, with Sep 2025 value amounting to -8.67%.

  • Journey Medical's EBIT Margin rose 1111.00% to -8.67% in Q3 2025 from the same period last year, while for Sep 2025 it was -9.25%, marking a year-over-year increase of 2193.00%. This contributed to the annual value of -24.36% for FY2024, which is 2175.00% down from last year.
  • As of Q3 2025, Journey Medical's EBIT Margin stood at -8.67%, which was up 54.74% from -19.16% recorded in Q2 2025.
  • In the past 5 years, Journey Medical's EBIT Margin ranged from a high of 49.93% in Q3 2023 and a low of -90.02% during Q2 2021.
  • For the 3-year period, Journey Medical's EBIT Margin averaged around -21.85%, with its median value being -19.70% (2024).
  • As far as peak fluctuations go, Journey Medical's EBIT Margin crashed by 7,813bps in 2021, and later surged by 10,883bps in 2023.
  • Journey Medical's EBIT Margin (Quarterly) stood at -51.70% in 2021, then tumbled by 1,090bps to -62.60% in 2022, then surged by 4,881bps to -13.79% in 2023, then surged by 3,019bps to 16.40% in 2024, then surged by 1,111bps to -8.67% in 2025.
  • Its EBIT Margin was -8.67% in Q3 2025, compared to -19.16% in Q2 2025 and -25.30% in Q1 2025.